Strategic-collaboration-with-EnaraBio Strategic-collaboration-with-EnaraBio Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
World Rabies Day 2020 sustainable dog vaccination World Rabies Day 2020 sustainable dog vaccination World Rabies Day 2020 sustainable dog vaccination
Rethinking mental health care Rethinking mental health care Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Boehringer Ingelheim advances SIRP immune-oncology program Boehringer Ingelheim advances SIRP immune-oncology program Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies
European_Commission_approves_nintedanibSSc-ILD European_Commission_approves_nintedanibSSc-ILD Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
clinical_collaboration_with_Mirati clinical_collaboration_with_Mirati Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
CHMP_opinion_nintedanib_ILD_PF CHMP_opinion_nintedanib_ILD_PF Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
New Partnership to Develop Gene Therapy for Cystic Fibrosis New Partnership to Develop Gene Therapy for Cystic Fibrosis Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
EC_approval_nintedanib_ILD_PF EC_approval_nintedanib_ILD_PF European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
CAROLINA-CARMELINA-Asia-analysis CAROLINA-CARMELINA-Asia-analysis CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Cystic Fibrosis Genetherapy Development Option Excercise Cystic Fibrosis Genetherapy Development Option Excercise Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
DCRI-collaboration-empact-mi DCRI-collaboration-empact-mi Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
emperor-reduced-heart-failure-toplineresults emperor-reduced-heart-failure-toplineresults Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
empa-reg-outcome-recurrent-events empa-reg-outcome-recurrent-events EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease